LB-42908 | 226927-89-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: LB-42908
• 英文别名: [1-{[1-(1,3-benzodioxole-5-ylmethyl)-1H-imidazole-5-yl]methyl}-4-(1-naphthyl)-1H-pyrrole-3yl](4-methyl-1-piperazinyl)methanone；1-[1-(3,4-methylenedioxybenzyl)-1H-imidazol-5-ylmethyl]-3-(4-methylpiperazin-1-yl)carbonyl-4-(naphthalen-1-yl)-1H-pyrrole；(1-((1-(benzo[d][1,3]dioxol-5-ylmethyl)-1H-imidazol-5-yl)methyl)-4-(naphthalen-1-yl)-1H-pyrrol-3-yl)(4-methylpiperazin-1-yl)methanone；[1-[[3-(1,3-benzodioxol-5-ylmethyl)imidazol-4-yl]methyl]-4-naphthalen-1-ylpyrrol-3-yl]-(4-methylpiperazin-1-yl)methanone
• CAS: 226927-89-5
• 化学式: C₃₂H₃₁N₅O₃
• 分子量: 533.63
• InChiKey: HWLBLFBLGGVDBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  40
• 可旋转键数：
  6
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  64.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  LB-42908 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 以31%的产率得到1-[2-azido-1-(3,4-methylenedioxybenzyl)-1H-imidazol-5-ylmethyl]-3-(4-methylpiperazin-1-yl)carbonyl-4-(naphthalen-1-yl)-1H-pyrrole
  参考文献：
  名称：

  Pyrrole derivatives useful for farnesyl transferase inhibitors and their preparations

  摘要：

  本发明涉及一种新型吡咯衍生物，其具有对法尼基转移酶的抑制活性，或其药学上可接受的盐或同分异构体；涉及一种制备该化合物的方法；以及一种制药组合物，如抗癌组合物等，包括该化合物作为活性成分，以及药学上可接受的载体。

  公开号：

  US06511978B1

文献信息

• Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease
  申请人：Exonhit Therapeutics SA

  公开号：EP1656931A1

  公开（公告）日：2006-05-17

  The invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention more specifically relates to new uses of compounds that inhibit the prenylation of proteins, in particular the geranylgeranyl and/or farnesyl modifications of proteins, for treating neurodegeneration involving oxidative stress and, more particularly, Parkinson's disease. The invention also relates to corresponding methods of treatment, and can be used in human subjects for preventive or curative treatment, either alone or in combination with other active agents or treatments.

  本发明涉及化合物及其用途，尤其是在制药业中的用途。本发明更具体地涉及抑制蛋白质的前酰化，特别是抑制蛋白质的香叶基和/或法呢基修饰的化合物的新用途，用于治疗涉及氧化应激的神经变性，特别是帕金森病。本发明还涉及相应的治疗方法，可用于人体的预防或治疗，可单独使用，也可与其他活性剂或治疗方法联合使用。
• IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF
  申请人：LG CHEMICAL LIMITED

  公开号：EP1045846B1

  公开（公告）日：2003-05-02
• FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF
  申请人：LG Chem Investment, Ltd.

  公开号：EP1169320B1

  公开（公告）日：2004-09-22
• COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON'S DISEASE
  申请人：Exonhit Therapeutics SA

  公开号：EP1811984A1

  公开（公告）日：2007-08-01
• PANEL OF BIOMARKERS FOR PREDICTION OF FTI EFFICACY
  申请人：Levitan Diane

  公开号：US20080090242A1

  公开（公告）日：2008-04-17

  The present invention provides, inter alia, methods for selecting a patient with cancer for treatment with a farnesyl protein transferase inhibitor as well as methods for treating said patient.